Original Research and the Latest News
Recent Posts
China Reshaping the Clinical Trial Pipeline
Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out...
Uncovering New Catalyst Events in the Pharmaceutical and Biotech Markets
The Challenges with Predicting Catalyst Events “Chasing headlines” for catalyst events in the biotech and pharmaceutical markets...
The Clinical Trial Powershift
Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of...
Finding the Needle in a Haystack with NLP
The problem with Big Data is that it is so Big! This issue is especially true in the world of healthcare and drug development. ...
Using Data to Optimize Clinical Trial Recruitment
The Importance of a High-Performing Clinical Trial Partnership Pharmaceutical companies are heavily dependent on clinical trials...
Healthiest States Index of The USA 2024
Health and wellness are pivotal for leading a wholesome life. Good health is a blessing. Time and health are the two most...
New Developments in Alzheimer’s Treatment
OZMOSI’s predictions for where Alzheimer's treatment is headed. The Ravaging Effects of Alzheimer’s The devastation of living...
FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug Development
FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval...
The Future of Innovation in Diabetes & Heart Disease
When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the...
Using NLP Data to Classify Patient Segments in Clinical Trial Data
One of the most common and powerful approaches in NLP provides the content experts an opportunity to label each data segment for...
Keeping up with the Pharmaceutical Industry in Asia
Keeping up with the pharmaceutical landscape around the world, especially in Asia, is essential in today’s market. Here are some...
Merck Diabetes Pipeline Analysis
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in...
New Faces in Big Pharma & the Rise of the Billion Dollar Deal
M&A mania is here. Unprecedented deal values for mergers and acquisitions dominated in 2014. Worldwide M&A was up...
Letting the Data Tell the Story
In our previous post we described the technique for assigning categories to data, based on input from content experts within a...
ELI LILLY in the Diabetes Market
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human...
Pharma Forecasting Case Study – Valuing the Impact of Development Delays
A multinational pharmaceutical firm asked Ozmosi to provide forecasts to assess the market impact of delays in delivering new...
Novo Nordisk Diabetes Pipeline Analysis
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a...
Covid-19 Clinical Trials and Where to Get Treated
We all know the basics for fighting the COVID-19 virus, like washing our hands and staying socially distant from one another,...
Recent Tweets
Get Started with OZMOSI
We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.
600 Warren Ave,
Spring Lake, NJ 07762